The Chain: Protein Engineering Podcast

The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.

The Chain: Protein Engineering Podcast is a science podcast hosted by Cambridge Healthtech Institute, with 91 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Cambridge Healthtech Institute hosts The Chain: Protein Engineering Podcast, a science show with 91 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #85

  Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating

  May 12, 202647 minS2

  <p><b>May 12, 2026</b> | When it comes to drug discovery, either you find a rare, clean target and everything clicks, or you spend a decade chasing biology that refuses to cooperate. Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, makes the case for a different playbook: objective-driven protein engineering, where we start with the outcome and design biologics that can execute it with built-in logic. With host Andrew Bradbury, Chen unpacks the SYNTHBODY platform and what “multi-tier logic gating” means in real drug design. They dive into logic-gated antibody drug conjugates, where target summation can boos...

  ListenShow Notes
• 

  Episode #84

  Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design

  Apr 15, 202639 minS2

  <p>How is BindCraft, the automated pipeline for de novo protein binder design, changing the protein design industry? Martin Pacesa, assistant professor of pharmacology at the University of Zurich, joins The Chain to discuss how BindCraft is helping non-protein designers learn how to design proteins—and how the role of the protein designer will evolve. With host Chris Bahl, their conversation explores how BindCraft may help with drug development, its role in the democratization of tools and resources, and how to work more collaboratively with AI models. Pacesa will also be speaking at May’s PEGS Summit in Boston.  </p><p><b>...

  ListenShow Notes
• 

  Episode #83

  Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement

  Mar 17, 202659 minS2

  <p>T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recognition of multiple targets, prospects for peptide MHC engagers and NK cells engagers, and the application of these modalities to oncology and...

  ListenShow Notes
• 

  Episode #82

  Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?

  Feb 10, 202649 minS2

  <p>During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderated by Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, the discussion centered around whether half-life extended pe...

  ListenShow Notes
• 

  Episode #81

  Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research

  Jan 13, 202644 minS2

  <p>How has immunotherapy evolved in the last decade? In this episode of The Chain, Laszlo Radvanyi, professor of immunology at the University of Toronto, discusses his years-long research on cancer immunotherapy, including his time at MD Anderson, with host Rakesh Dixit. He shares his thoughts on agonist antibodies, the true breakthroughs that are moving the needle for patients, reducing the CD-28 pathway so that it doesn’t produce cytokine toxins, and what is the next frontier in immunotherapy. <br/><br/><b>Links from this episode: </b> <br/>EpiVax <br/>University of Toronto, Department of Immunology <br/>University of Toronto </p><p>

  ListenShow Notes

Recent guests on The Chain: Protein Engineering Podcast. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.